Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India

Clinical Infectious Diseases

Volumn 59, Issue 10, 2014, Pages e142-e149

  Velayutham, Banurekha V ^a   Allaudeen, Iliayas S ^a   Sivaramakrishnan, Gomathi N ^a   Perumal, Venkatesan ^a   Nair, Dina ^a   Chinnaiyan, Ponnuraja ^a   Paramasivam, Paul K ^a   Dhanaraj, Baskaran ^a   Santhanakrishnan, Ramesh K ^a   Navaneethapandian, Gangadevi P ^a   Marimuthu, Makesh K ^a   Kumar, Vanaja ^a   Kandasamy, Chandrasekaran ^a   Dharuman, Kalaiselvi ^a   Elangovan, Thiruvalluvan ^a   Narasimhan, Meenakshi ^b   Rathinam, Sridhar ^c   Vadivelu, Gangadharan ^d   Rathinam, Prabhakaran ^e   Chockalingam, Chandrasekar ^f   Jayabal, Lavanya ^g   Swaminathan, Soumya ^a   Shaheed, Jawahar M ^a   more..

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b Institute of Thoracic Medicine   (India)

^c STANLEY MEDICAL COLLEGE   (India)

^d Government Thiruvateeswarar Hospital   (India)

^e Government Rajaji Hospital   (India)

^f Government Hospital for Thoracic Medicine   (India)

^g Chennai Corporation   (India)

Author keywords

Culture conversion; Intensive phase; Moxifloxacin; Sputum conversion; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; DIABETES MELLITUS; DRUG ERUPTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; INDIA; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT COMPLIANCE; PRURITUS; SEIZURE; SEROCONVERSION; SPUTUM CULTURE; THORAX RADIOGRAPHY; TOXIC HEPATITIS; ANTIBIOTIC RESISTANCE; DRUG ADMINISTRATION; DRUG COMBINATION; MICROBIOLOGY; MIDDLE AGED; REGISTER; RISK FACTOR; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; INDIA; MALE; MIDDLE AGED; RADIOGRAPHY, THORACIC; REGISTRIES; RISK FACTORS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84918802672     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu550     Document Type: Article

References (26)

1. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-71.
2. Tuberculosis Research Centre. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tuberc 2002;49:27-38.
3. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-9.
4. Yoshimatsu T, Nuermberger EL, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002;46:1875-9.
5. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-6.
6. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-4.
7. Wang JY, Wang JT, Tsai TH, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010;14:65-71.
8. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-9.
9. Kent PT, Kubica GP. Isolation procedures. In: Public health mycobacteriology: a guide for level 3 laboratory. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1985:42-3.
10. Standard Operating Procedures for Mycobacteriology Laboratory, Department of Bacteriology, Tuberculosis Research Centre. ICMR, 2010. Available at: http://nirt.res.in/pdf/bact/SOP.pdf. Accessed 23 July 2014.
11. Allen B, Baker FJ. Mycobacteria: isolation, identification and sensitivity testing. London: Butterworths, 1968.
12. Kubica GP. Differential identification of mycobacteria. VII: key features for identification of clinically significant mycobacteria. Am Rev Respir Dis 1973;107:9-21.
13. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva, Switzerland: WHO/HTM/TB, 2008:392.
14. Subbammal S, Nair NGK, Radhakrishna S, Tripathy SP. Comparison of various measures of sensitivity of Mycobacterium tuberculosis to ethambutol. Tubercle 1978;59:185-91.
15. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of the sensitivity tests in tuberculosis control programs. Bull WHO 1969;41:21-43.
16. Sulochana S, Venkataraman P, Paramasivan CN. Evaluation of various methods of susceptibility to ofloxacin in strains of Mycobacterium tuberculosis. Indian J Med Res 1999;110:186-9.
17. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8.
18. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80.
19. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364:1244-51.
20. Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 2013;8:e67030.
21. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-3.
22. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in south India. Am Rev Respir Dis 1986;134:27-33.
23. Phillips PPJ, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 2013;8:e63840.
24. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and metaanalysis. Lancet Infect Dis 2010;10:387-94.
25. El Sahly HM, Teeter LD, Jost KC Jr, Dunbar D, Lew J, Graviss EA. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. J Clin Microbiol 2011;49:2942-5.
26. Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a metaregression model. PLoS One 2013;8:e71116.